Malignancies other than NSCLC within  years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated expected curative outcome
Malignancies other than TNBC within  years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer)
Active malignancies within  months with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
Malignancies other than head and neck cancer within  years prior to Day  of treatment, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
Malignancies other than UCa within  years prior to Day , with the exception of those with negligible risk of metastasis or death treated with expected curative outcome;
Active malignancies within  years except for those with a negligible risk of metastasis or death treated with expected curative outcome.
Patients who have known additional malignancies other than UBC within  years before initiation of study treatment; exceptions include malignancies with a negligible risk of metastasis or death and treated with expected curative outcome (e.g., nonmelanomatous skin cancers), or localized prostate cancer treated with curative intent and absence of prostate-specific antigen (PSA) relapse or incidental prostate cancer
Malignancies other than SCLC within  years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
Malignancies other than NSCLC within  years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
Malignancies other than UBC within  years prior to Cycle , Day , with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome, or localized prostate cancer treated with curative intent and absence of prostate-specific antigen (PSA) relapse or incidental prostate cancer
Malignancies other than urothelial bladder cancer within  years prior to Cycle , Day , with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome or incidental prostate cancer
Malignancies other than NSCLC within  years prior to randomization, with the exception of those with negligible risk of metastases or death and treated with expected curative outcome
Active malignancies within the past  months except negligible risk of metastasis or death treated with expected curative outcome.
Active malignancies within  months with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome.
Malignancies other than NSCLC within  years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
Malignancies other than triple negative breast cancer (TNBC) within  years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer)
Malignancies within  years prior to enrollment, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome